目的 探討潤(rùn)肺止嗽丸聯(lián)合布地奈德福莫特羅治療慢性阻塞性肺疾病緩解期的臨床療效。方法 選取2020年6月—2022年12月定州市人民醫(yī)院收治的128例慢性阻塞性肺疾病緩解期患者，按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各64例。對(duì)照組患者經(jīng)口吸入布地奈德福莫特羅粉吸入劑，1～2吸/次，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服潤(rùn)肺止嗽丸，2丸/次，2次/d。兩組均連續(xù)治療8周。治療后，比較兩組癥狀緩解時(shí)間、肺功能指標(biāo)和血清炎性因子水平。結(jié)果 治療后，治療組總有效率是98.44%，顯著高于對(duì)照組的84.38%（P＜0.05）。治療后，治療組咳嗽、咳痰、氣短、疲乏緩解時(shí)間均顯著短于對(duì)照組（P＜0.05）。治療后，兩組第1秒用力呼氣容積（FEV1）、用力肺活量（FVC）、FEV1占預(yù)測(cè)值百分比（FEV1%）均較治療前顯著升高（P＜0.05）；治療后，治療組FEV1、FVC、FEV1%均高于對(duì)照組（P＜0.05）。治療后，兩組患者白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、血清內(nèi)皮素-1（ET-1）水平均較治療前顯著降低，而降鈣素基因相關(guān)肽（CGRP）水平均顯著提高（P＜0.05）；治療后，治療組血清炎性因子水平改善優(yōu)于對(duì)照組（P＜0.05）。結(jié)論 潤(rùn)肺止嗽丸聯(lián)合布地奈德福莫特羅粉治療慢性阻塞性肺疾病緩解期效果確切，可有效緩解患者臨床癥狀，改善肺功能指標(biāo)，調(diào)節(jié)血清炎性細(xì)胞因子水平，值得臨床借鑒推廣。

Objective To investigate the clinical effect of Runfei Zhisou Pills combined with budesonide and formoterol fumarate powder in chronic obstructive pulmonary disease in remission stage. Methods A total of 128 patients with chronic obstructive pulmonary disease in remission period admitted to Dingzhou People's Hospital from June 2020 to December 2022 were selected and divided into control group and treatment group according to random number table method, with 64 patients in each group. Patients in the control group inhaled Budesonide and Formoterol Fumarate Powder for inhalation orally, 1-2 puffs/time, twice daily. Patients in the treatment group were po administered with Runfei Zhisou Pills on the basis of the control group, 2 pills/time, twice daily. Both groups were treated continuously for 8 weeks. After treatment, symptom remission time, pulmonary function indexes and serum inflammatory factors levels were compared between two groups. Results After treatment, the total effective rate of the treatment group was 98.44%, which was significantly higher than that of the control group (84.38%, P < 0.05). After treatment, the relief time of cough, expectoration, shortness of breath and fatigue in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and the percentage of FEV1 to predicted value (FEV1%) of both groups were significantly increased compared with those before treatment (P < 0.05). After treatment, FEV1, FVC and FEV1% in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and serum endothelin-1 (ET-1) in two groups were significantly decreased compared with before treatment, while the levels of CGRP were significantly increased (P < 0.05). After treatment, the level of serum inflammatory factors in treatment group was better than that in control group (P < 0.05). Conclusion Runfei Zhisou Pills combined with budesonide and formoterol fumarate has a definite effect in chronic obstructive pulmonary disease in remission stage, and can improve lung function indicators, regulate the level of serum inflammatory cytokines, which is worthy of clinical reference and promotion.

R974

河北省醫(yī)學(xué)科學(xué)研究課題（20191747）